Leukemias are monoclonal diseases that arise from cells in the hematopoietic stem and progenitor cell compartment. Consistent with emerging models of carcinogenesis, leukemogenesis is an evolutionary process that involves multiple independent genetic and epigenetic events. Over the last half-century a predominant paradigm has emerged to describe leukemia developing secondary to alkylating drug therapy or exposure to benzene in which progressive dysplastic changes, accompanied by a distinct pattern of clonal cytogenetic abnormalities, give rise to acute myelogenous leukemia. Characterization of these clonal chromosomal aberrations, together with observed alterations in other growth-promoting genes, provides a useful framework for studying chemical leukemogenesis and for use in understanding the origins and development of leukemia in general.
Process of Leukemogenesis
Leukemias are monoclonal diseases that originate from individual cells in the bone marrow. Like other cancers, leukemias often exhibit a progression in their natural history from cells that possess a phenotype exhibiting some remnant of normal differentiation to the progressive loss of maturation ability and the development of an aggressive undifferentiated malignant phenotype (1) . A common characteristic of malignant neoplasms, including leukemias, is abnormal regulation of cell growth. A particular challenge to understanding the role of altered regulation of cell growth in the development of leukemia is that differences in the behavior between normal and malignant hematopoietic cells are often subtle. For example, normal hematopoietic progenitor cells possess some characteristics common to malignant cells, among them: the ability to proliferate, survive intravascular transit, and transmigrate into tissues, and the ability to grow in semisolid media. On the other hand, leukemic cells often do not exhibit total growth-factor independence when first introduced into culture.
Consistent with present models for the origin and progression of neoplasia, leukemia development has long been thought to be a multistep process. Foulds first proposed a multistep progression in which a normal cell must pass through a number of distinct intermediate stages before a frank malignancy develops (2, 3) . Since that time, a variety of independent observations have emerged to support the conclusion that cancer in general is an evolutionary process in which multiple events involving independent genetic alterations in protooncogenes or suppressor genes together with epigenetic or environmental factors contribute to the development of the full malignant phenotype (4, 5) . The This paper was presented at Benzene '95: An International Conference on the Toxicity, Carcinogenesis, and Epidemiology of Benzene held 17-20 June 1995 in Piscataway, New Jersey. Manuscript received 16 January best understood example of carcinogenesis in a normal, rapidly proliferating tissue is carcinoma of the colon, in which it appears that as many as five independent genetic and epigenetic changes may be required for the progression of a normal epithelial cell to a carcinoma cell (6, 7) (Figure 1 ). This model is based on the seminal observation by Vogelstein et al. that the incidence of ras-gene mutations increased dramatically as a function of the size and malignant phenotype of the tumor and that four molecular alterations accumulated in a manner that paralleled the clinical and histopathological progression of the tumor (7) . In addition to illustrating the multifactorial nature of cancer development, these correlative studies reveal that the precise sequence of events is not a constant but that individual tumors can vary in their evolution.
Regulation of Hematopoiesis
A great deal of evidence suggests that protooncogenes and other growth-promoting genes such as those encoding for cytokines or their receptors play an important role in carcinogenesis and malignant transformation. Recent advances in cell and molecular biology have revolutionized our understanding of the regulation of growth in normal hematopoiesis. Therefore, a brief summary of the functions of cytokines in regulating normal hematopoiesis provides a logical foundation for a discussion of the mechanisms of altered cell growth and differentiation occurring in leukemogenesis. Three fundamental cellular processes that define hematopoietic cells are survival, proliferation, and differentiation. The survival and proliferation of hematopoietic progenitor cells (HPC) are controlled by multiple growth factors or cytokines with overlapping functions that act individually or in combination to regulate hematopoiesis (8). Recent studies support the conclusion that either interleukin-3 (IL-3) or granulocyte/macrophage-colony-stimulating factor (GM-CSF) are required to sustain the viability of stem cells or early HPC. Early HPC can also be recruited into active cycle in response to these same cytokines or a second stimulus such as c-kit ligand (CKL), IL-6, or granulocyte colony-stimulating factor (G-CSF) (9-11). Later (1, (29) (30) (31) (32) . Over the past decade the term preleukemia has been largely supplanted by the more functional classification of the myelodysplastic syndromes (MDS) by the fast atom bombardment (FAB) (33). Differences in growth and differentiation between MDS and AML find analogy in the progression of solid tissue tumors from metaplasia and dysplasia to carcinoma. This observation, together with the frequent progression of secondary s-MDS to frank AML, leads to the inescapable conclusion that MDS and AML should be considered a single disease continuum when viewed in the context of chemical leukemogenesis.
As a secondary malignancy, AML clearly dominates the leukemia literature. At present, the world literature contains approximately 38,000 cases of individuals treated with alkylating agents or radiation for primary malignancies or immune disorders that have been followed for development of secondary malignancies, the most prominent of which is AML. These typically involve MI, M2, M4, M6, but not M3 or M5 subtypes of AML, based on the FAB classification system (34,35). From these studies at least 1322 cases of AML and 320 cases of MDS have been reported (29, 30, . If one includes all cases attributed to solvent exposure in general or benzene specifically, whether anecdotal or reported in case-control or cohort studies, the total number of secondary leukemias approaches 2100, over 96% of which are MDS/AML (44,58-70). The frequency of secondary AML/MDS varies markedly depending on individual therapeutic regimen but historically has ranged between 0.6 and 17%, with relative risks averaging about 100-fold (range 9-320 X). These studies establish a consistent and very strong pattern in which the development of AML is preceded by a period of preleukemia in 33 to 80% of the cases and is accompanied by clonal cytogenetic abnormalities involving loss of all or part of chromosomes 5 and 7 (Table 1) . On average the frequency of deletions or loss of chromosomes 5 and 7 in studies of patients who develop MDS or AML after antineoplastic therapy ranges between 85 and 95% (71) (72) (73) (74) (75) (76) . The same cytogenetic abnormalities occur much less frequently in de novo AML: in 660 de novo cases chromosomes 5 and 7 were observed in 4.2 and 4.4%, respectively, and simultaneously in 3.2% (77, 78) . Consistent with the evolution of s-AML described previously, most patients presenting with clonal chromosomal aberrations involving the loss of all or part of chromosomes 5 or 7 exhibit a preleukemic phase prior to the onset of AML (79 suggests that the relevant genetic event may be the deletion of a critical gene sequence rather than consistent juxtaposition of DNA sequences that may occur in chromosome translocation ( Figure 2 ) (73). A cluster of genes involved in the regulation of hematopoiesis is located at q3 1 on chromosome 5 ( Figure 3 ). These include GM-CSF, IL-3, IL-4, IL-5, CD14 (which encodes a myeloid-specific surface molecule that has structural characteristics of a receptor), and early growth response 1 (EGRI) (an EGR gene with fos-like properties) (88). There is no evidence for homozygous deletion of any of these genes in AML, such as has been described for retinoblastoma in which the absence of one allele of retinoblastoma gene is followed by a second somatic mutation, resulting in loss of both copies of the gene (89) . The most consistent deletion associated with 5q31-appears to involve the loss of one allele encoding either GM-CSF or EGR1 (88) . Close to, but lying outside of, the critical region is the protooncogene, c-fins, the receptor for M-CSF that acts exclusively on cells of monomacrophage lineage (90 In addition to early involvement of genes on chromosome 5, a growing number of protooncogenes have been reported to undergo structural or functional alterations in AML with widely differing frequency. These have been the subject of a number of reviews (5, (92) (93) (94) . To date, no single or consistent pattern of protooncogene involvement has been associated with AML development, suggesting that multiple genes may interact via different pathways in the evolution of the disease. This discussion will focus only on a small number of these genes. The human ras genes encode p2l proteins that appear to play an important role as second messengers in tyrosine kinase receptor-mediated signal transduction (95) . It has been hypothesized that ras mutations may feature prominently in the development of s-AML (96) . However, what role ras mutations play in the development of either de novo or s-AML remains uncertain. In a large number of studies, ras protooncogene activation, principally N-RAS, has been variously reported to occur in about 25% of cases of de novo AML (92, 95) . However, clonal chromosomal aberrations have been demonstrated to precede ras involvement in the evolution of the disease (97, 98) and, when identified, ras mutations tend to be present only in subclones of the leukemic cells (97, 99) . To date, RAS involvement has not proven to be either a prognostic indicator or to correlate with FAB subtype. From these studies it appears that ras mutation is an unlikely early event in AML and is insufficient to cause the disease. However, ras activation can occur at a number of stages in the development of AML and it cannot be excluded that RAS may play a role in the evolution or progression of at least some cases of AML (100). The p53 gene encodes a phosphoprotein nuclear transcription factor that is spatially regulated within the cell during the cell cycle. The wild-type protein is known to limit cell growth apparently by two independent mechanisms: mediating apoptosis and as a checkpoint, regulating the length of GJ (101) . Often referred to as a tumor suppressor gene, inactivation of p53 is an important event in the transformation of many tumors and is the most frequently encountered gene mutation in human cancer (102) 
A Model for Leukemogenesis
Up to this point the discussion has focused exclusively on the role of clonal hematopoietic stem and progenitor cell abnormalities in the development and evolution of MDS/AML. Another hypothesis has been proposed in which altered growth factor production by fibroblasts, endothelial cells, and macrophages may feature prominently in the development of leukemias (108) . As the basis for a stand-alone theory of leukemogenesis, each of these alternatives possesses individual strengths and weaknesses. A diverse set of observations argues persuasively that the ultimate clonal derivation of most cases of AML and MDS are HPC essentially restricted to the myeloid lineage (109) (110) (111) (112) than the exception in the evolution of s-AML, and abnormal cytokine production is frequently encountered in cases of MDS/AML (113) (114) (115) (116) . Alternatively, one can propose an integrative model of leukemogenesis that is compatible with both donal and microenvironmental involvement in the development and progression of these myeloproliferative disorders. In hematopoiesis, there is considerable evidence that cell viability and cell growth are functions that can be dissociated (117). Raza et al. (118, 119) have recently reported an increase in both cell turnover and apoptosis in bone marrow of patients with MDS relative to normal bone marrow that is in sharp contrast to AML, in which proliferation is high but the frequency of apoptotic cells is low. A chromosomal aberration in an early progenitor cell could result in allelic deletion of one GM-CSF gene, resulting in a commensurate decrease in intracellular GM-CSF. Using antisense technology, Pech and coworkers provide evidence that low-level autocrine regulation of GM-CSF may regulate survival in early progenitor cells independent of exogenous GM-CSF that is associated with proliferation (120). If intracellular GM-CSF were insufficient to suppress apoptosis in maturing cells of the affected clone, a corresponding increase in exogenous GM-CSF occurring in physiologic response to increased apoptosis would drive cell proliferation, leading to an increase in overall cell turnover in the affected clone. This model is consistent with the regulatory paradox in MDS in which bone marrow hyperplasia is accompanied by ineffective hematopoiesis and cytopenias. Subsequent events involving genes linked directly or indirectly to cell survival and maturation (e.g., ras, p53, or Rb) could enable the escape of the subclone from the apoptotic treadmill and development of a frank AML (Figure 4) . This model is only one possible explanation for the origins and progression of leukemia that is compatible with roles for both clonal and microenvironmental events. The earliest observations associated with the development of MDS/AML suggest that a relatively small number of alternative events predispose the development of leukemia. These most likely involve a clonal chromosomal abnormality together with altered regulation of cytokine response. However, the diversity of gene involvement in later stages of AML progression is consistent with an emerging pattern in cancer biology in which multiple alternative genetic pathways converge in the development of a specific tumor type. 
